Kiadis Pharma NV (Kiadis Pharma NV) Total Stockholders Equity : $-40.05 Mil (As of Dec. 2020)

View and export this data going back to 2016. Start your Free Trial

What is Kiadis Pharma NV Total Stockholders Equity?

Kiadis Pharma NV's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $-40.05 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kiadis Pharma NV's Book Value per Share for the quarter that ended in Dec. 2020 was $-0.99. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kiadis Pharma NV's Debt-to-Equity for the quarter that ended in Dec. 2020 was -0.43.

Kiadis Pharma NV Total Stockholders Equity Historical Data

The historical data trend for Kiadis Pharma NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Total Stockholders Equity Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Stockholders Equity

Get a 7-Day Free Trial

9.96

18.77

50.22

38.06

-40.05

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
Total Stockholders Equity	Get a 7-Day Free Trial											50.22	67.46	38.06	31.07	-40.05

Kiadis Pharma NV (GREY:KIADF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kiadis Pharma NV's Book Value per Share for the quarter that ended in Dec. 2020 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-40.047	-	0)	/	40.3085
	=	-0.99

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kiadis Pharma NV's Debt-to-Equity for the quarter that ended in Dec. 2020 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.877	+	6.527)	/	-40.047
	=	-0.43

Kiadis Pharma NV Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (Kiadis Pharma NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (GREY:KIADF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (Kiadis Pharma NV) Headlines

No Headlines